A blueprint for a healthier tomorrow

We design and develop precision therapies, with the goal of transforming patient care. These include multiple programs for genomically defined cancers, rare diseases and cancer immunotherapy.

Our pipeline

A blueprint for a healthier tomorrow

We design and develop precision therapies, with the goal of transforming patient care. These include multiple programs for genomically defined cancers, rare diseases and cancer immunotherapy.

Our pipeline

Powerful precision

Our uniquely targeted, scalable approach empowers the rapid design and development of new precision therapies and increases the likelihood of clinical success.

Our platform

A promise to change the paradigm

We strive to improve human health with transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease.

Our company

Diversity sparks imagination

Our diverse team is passionate about science and thrives on working together to achieve the impossible. We use every opportunity to think differently, make bold decisions and pioneer novel solutions.

Our opportunities

Our 2020 Blueprint

2 marketed products
4 pending
marketing
applications
6 clinical-stage
therapeutic
candidates
8 research
programs

Our “2020 Blueprint” strategy establishes a planned path to transform Blueprint Medicines, by the end of 2020, into a global commercial enterprise focused on delivering a portfolio of precision therapies to patients with cancer and rare diseases. See our press release.

Our commitment to patients

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.

Read on

Our investigational precision therapies

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

Avapritinib

Development programs

  • Advanced gastrointestinal stromal tumors
  • Advanced systemic mastocytosis
  • Indolent and smoldering systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

BLU-667

Development programs

  • Advanced RET-fusion non-small cell lung cancer
  • Advanced medullary thyroid cancer
  • Other RET-altered solid tumors
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

BLU-554

Development programs

  • Advanced hepatocellular carcinoma
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

BLU-782

Development programs

  • Fibrodysplasia ossificans progressiva
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (CSTI).

Meet the Blue Crew

Meet the Blue Crew

Corinne, Senior Clinical Program Manager

I lead clinical operations for BLU-667, an investigational therapy for people with RET-altered cancers. My job is to plan and lead clinical trials to support our goal of delivering this potentially transformative new medicine to patients quickly and responsibly.

Read on
The Lens

We aspire to pioneer new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit The Lens.

Read on
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Jeff Albers,
Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Jeff Albers, Chief Executive Officer

Dare to be different

A strong team embraces different perspectives, opinions and ideas. We believe each level of our company should reflect our team’s diversity—and its excellence.

Read on